SEARCH

SEARCH BY CITATION

References

  • ACHIWA, H.., YATABE, Y.., HIDA, T.., KUROISHI, T.., KOZAKI, K.., NAKAMURA, S.., OGAWA, M.., SUGIURA, T.., MITSUDOMI, T.. & TAKAHASHI, T.. (1999). Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res., 5, 10011005.
  • BAKER, D.., PRYCE, G.., GIOVANNONI, G.. & THOMPSON, A.J.. (2003). The therapeutic potential of cannabis. Lancet Neurol., 2, 291298 Review.
  • BARSKY, S.H.., ROTH, M.D.., KLEERUP, E.C., SIMMONS, M. & TASHKIN, D.P. (1998). Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J. Natl. Cancer Inst., 90, 11981205.
  • BEN-SHABAT, S., FRIDE, E., SHESKIN, T., TAMIRI, T., RHEE, M.H., VOGEL, Z., BISOGNO, T., DE PETROCELLIS, L., DI MARZO, V. & MECHOULAM, R. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol., 353, 2331.
  • BERRENDERO, F., SEPE, N., RAMOS, J.A., DI MARZO, V. & FERNANDEZ-RUIZ, J.J. (1999). Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse, 33, 181191.
  • BHARGAVA, H.N., HOUSE, R.V., THORAT, S.N. & THOMAS, P.T. (1996). Cellular immune fuction in mice tolerant to or abstinent from 1-trans-Δ-9-tetrahydrocannabinol. Pharmacology, 52, 271.
  • BIFULCO, M. & DI MARZO, V. (2002). Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat. Med., 8, 547550.
  • BIFULCO, M., LAEZZA, C., PORTELLA, G., VITALE, M., ORLANDO, P., DE PETROCELLIS, L. & DI MARZO, V. (2001). Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J., 15, 27452747.
  • BIFULCO, M., LAEZZA, C., VALENTI, M., LIGRESTI, A., PORTELLA, G. & DI MARZO, V. (2004). A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J., 18, 16061608.
  • BLAZQUEZ, C., CASANOVA, M.L., PLANAS, A., DEL PULGAR, T.G., VILLANUEVA, C., FERNANDEZ-ACENERO, M.J., ARAGONES, J., HUFFMAN, J.W., JORCANO, J.L. & GUZMAN, M. (2003). Inhibition of tumor angiogenesis by cannabinoids. FASEB J., 17, 529531.
  • BLAZQUEZ, C., GONZALEZ-FERIA, L., ALVAREZ, L., HARO, A., CASANOVA, M.L. & GUZMAN, M. (2004). Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res., 64, 56175623.
  • BOUABOULA, M., POINOT-CHAZEL, C., BOURRIE, B., CANAT, X., CALANDRA, B., RINALDI-CARMONA, M., LE FUR, G. & CASELLAS, P. (1995). Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J., 312 (Part 2), 637641.
  • BRENNEISEN, R., EGLI, A., ELSOHLY, M.A., HENN, V. & SPIESS, Y. (1996). The effect of orally and rectally administered Δ9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int. J. Clin. Pharmacol. Ther., 34, 446452.
  • BRUEGGEMEIER, R.W., QUINN, A.L., PARRETT, M.L., JOARDER, F.S., HARRIS, R.E. & ROBERTSON, F.M. (1999). Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett., 140, 2735.
  • CARAYON, P., MARCHAND, J., DUSSOSSOY, D., DEROCQ, J.M., JBILO, O., BORD, A., BOUABOULA, M., GALIEGUE, S., MONDIERE, P., PENARIER, G., FUR, G.L., DEFRANCE, T. & CASELLAS, P. (1998). Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood, 92, 36053615.
  • CARRACEDO, A., GEELEN, M.J., DIEZ, M., HANADA, K., GUZMAN, M. & VELASCO, G. (2004). Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids. Biochem J., 380 (Part 2), 435440.
  • CASANOVA, M.L., BLAZQUEZ, C., FERNANDEZ-ACENERO, M.J., VILLANUEVA, C., JORCANO, J. & GUZMAN, M. (2001). CB1 and CB2 receptors are expressed in the skin and their activation inhibits the growth of skin cancer cells, Symposium on Cannabinoids, Vol. 1, p. 151, International Cannabinoid Research Society: Burlington, VT.
  • CASANOVA, M.L., BLAZQUEZ, C., MARTINEZ-PALACIO, J., VILLANUEVA, C., FERNANDEZ-ACENERO, M.J., HUFFMAN, J.W., JORCANO, J.L. & GUZMAN, M. (2003). Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest., 111, 4350.
  • CASANOVA, M.L., LARCHER, F., CASANOVA, B., MURILLAS, R., FERNANDEZ-ACENERO, M.J., VILLANUEVA, C., MARTINEZ-PALACIO, J., ULLRICH, A., CONTI, C.J. & JORCANO, J.L. (2002). A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res., 62, 34023407.
  • CHAN, P.C., SILLS, R.C., BRAUN, A.G., HASEMAN, J.K. & BUCHER, J.R. (1996). Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam. Appl. Toxicol., 30, 109117.
  • CLEVENGER, C.V., CHANG, W.P., NGO, W., PASHA, T.L., MONTONE, K.T. & TOMASZEWSKI, J.E. (1995). Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am. J. Pathol., 146, 695705.
  • CONSROE, P., KENNEDY, K. & SCHRAM, K. (1991). Assay of plasma cannabidiol by capillary gas chromatography ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol. Biochem. Behav., 40, 517522.
  • CORASANITI, M.T., STRONGOLI, M.C., PICCIRILLI, S., NISTICO, R., COSTA, A., BILOTTA, A., TURANO, P., FINAZZI-AGRO, A. & BAGETTA, G. (2000). Apoptosis induced by gp120 in the neocortex of rat involves enhanced expression of cyclooxygenase type 2 and is prevented by NMDA receptor antagonists and by the 21-aminosteroid U-74389G. Biochem. Biophys. Res. Commun., 274, 664669.
  • COTA, D., MARSICANO, G., TSCHOP, M., GRUBLER, Y., FLACHSKAMM, C., SCHUBERT, M., AUER, D., YASSOURIDIS, A., THONE-REINEKE, C., ORTMANN, S., TOMASSONI, F., CERVINO, C., NISOLI, E., LINTHORST, A.C., PASQUALI, R., LUTZ, B., STALLA, G.K. & PAGOTTO, U. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest., 112, 423431.
  • DE PETROCELLIS, L., BISOGNO, T., DAVIS, J.B., PERTWEE, R.G. & DI MARZO, V. (2000). Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett., 483, 5256.
  • DE PETROCELLIS, L., BISOGNO, T., LIGRESTI, A., BIFULCO, M., MELCK, D. & DI MARZO, V. (2002). Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam. Clin. Pharmacol., 16, 297302.
  • DE PETROCELLIS, L., MELCK, D., PALMISANO, A., BISOGNO, T., LAEZZA, C., BIFULCO, M. & DI MARZO, V. (1998). The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. U.S.A., 95, 83578380.
  • DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 19461949.
  • DI MARZO, V. (1998). Endocannabinoids and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta, 1392, 153175.
  • DI MARZO, V., BIFULCO, M. & DE PETROCELLIS, L. (2004). The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov., 3, 771784 Review.
  • DI MARZO, V., BREIVOGEL, C.S., TAO, Q., BRIDGEN, D.T., RAZDAN, R.K., ZIMMER, A.M., ZIMMER, A. & MARTIN, B.R. (2000). Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem., 75, 24342444.
  • DI MARZO, V., DE PETROCELLIS, L., FEZZA, F., LIGRESTI, A. & BISOGNO, T. (2002). Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids, 66, 377391.
  • DI MARZO, V., MELCK, D., ORLANDO, P., BISOGNO, T., ZAGOORY, O., BIFULCO, M., VOGEL, Z. & DE PETROCELLIS, L. (2001). Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J., 358, 249255.
  • DISTLER, J.H., HIRTH, A., KUROWSKA-STOLARSKA, M., GAY, R.E., GAY, S. & DISTLER, O. (2003). Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q. J. Nucl. Med., 47, 149161 Review.
  • EBERHART, C.E., COFFEY, R.J., RADHIKA, A., GIARDIELLO, F.M., FERRENBACH, S. & DUBOIS, R.N. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 11831188.
  • EGAN, K.M., LAWSON, J.A., FRIES, S., KOLLER, B., RADER, D.J., SMYTH, E.M. & FITZGERALD, G.A. (2004). COX-2 derived prostacyclin confers atheroprotection on female mice. Science, 306, 19541957.
  • ELDER, D.J., BAKER, J.A., BANU, N.A., MOORGHEN, M. & PARASKEVA, C. (2002). Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J. Pathol., 198, 428434.
  • ELLERT-MIKLASZEWSKA, A., KAMINSKA, B. & KONARSKA, L. (2005). Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal., 17, 2537.
  • FELDER, C.C. & GLASS, M. (1998). Cannabinoid receptors and their endogenous agonists. Annu. Rev. Pharmacol. Toxicol., 38, 179200 Review.
  • GALIEGUE, S., MARY, S., MARCHAND, J., DUSSOSSOY, D., CARRIERE, D., CARAYON, P., BOUABOULA, M., SHIRE, D., LE FUR, G. & CASELLAS, P. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 232, 5461.
  • GALVE-ROPERH, I., SANCHEZ, C., CORTES, M.L., DEL PULGAR, T.G., IZQUIERDO, M. & GUZMAN, M. (2000). Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med., 6, 313319.
  • GARDNER, B., ZHU, L.X., SHARMA, S., TASHKIN, D.P. & DUBINETT, S.M. (2003). Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J., 17, 21572159.
  • GIERINGER, D. (2001). Cannabis ‘vaporization’: a promising strategy for smoke harm reduction. J. Cannabis Ther., 1, 153170.
  • GOKOH, M., KISHIMOTO, S., OKA, S., MORI, M., WAKU, K., ISHIMA, Y. & SUGIURA, T. (2005). 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. Biochem J., 386, 583589.
  • GOMEZ DEL PULGAR, T., VELASCO, G., SANCHEZ, C., HARO, A. & GUZMAN, M. (2002). De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J., 363, 183188.
  • GRIMALDI, C., PISANTI, S., LAEZZA, C., MALFITANO, A.M., SANTORO, A., VITALE, M., CARUSO, M.G., NOTARNICOLA, M., IACUZZO, I., PORTELLA, G., DI MARZO, V. & BIFULCO, M. (2006). Anandamide inhibits adhesion and migration of breast cancer cells. Exp. Cell. Res., 312, 363373.
  • GROTENHERMEN, F. (2001). Harm reduction associated with inhalation and oral administration of cannabis and THC. J. Cannabis Ther., 1, 133152.
  • GRUNSTEIN, J., ROBERTS, W.G., MATHIEU-COSTELLO, O., HANAHAN, D. & JOHNSON, R.S. (1999). Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res., 59, 15921598.
  • GUZMAN, M. (2003). Cannabinoids: potential anticancer agents. Nat. Rev. Cancer, 3, 745755.
  • GUZMAN, M., GALVE-ROPERH, I. & SANCHEZ, C. (2001a). Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol. Sci., 22, 1922 Review.
  • GUZMAN, M., SANCHEZ, C. & GALVE-ROPERH, I. (2001b). Control of the cell survival/death decision by cannabinoids. J. Mol. Med., 78, 613625.
  • GUZMAN, M., SANCHEZ, C. & GALVE-ROPERH, I. (2002). Cannabinoids and cell fate. Pharmacol. Ther., 95, 175184 Review.
  • HALL, W., MACDONALD, C. & CURROW, D. (2005). Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol., 6, 3542 Review.
  • HALL, W.D. & MACPHEE, D. (2002). Cannabis use and cancer. Addiction, 97, 243247.
  • HAMELERS, I.H.L., VANSCHAIK, R.F.M.A., SUSSENBACK, J.S. & STEENBERGH, P.H. (2003). 17b-Estradiol responsiveness of MCF-7 laboratory strains is dependent on an autocrine signal activating the IGF type I receptor. Cancer Cell Int., 3, 1020.
  • HART, S., FISCHER, O.M. & ULLRICH, A. (2004). Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res., 64, 19431950.
  • HINZ, B. & BRUNE, K. (2002). Cyclooxygenase-2–10 years later. J. Pharmacol. Exp. Ther., 300, 367375 Review.
  • HINZ, B., RAMER, R., EICHELE, K., WEINZIERL, U. & BRUNE, K. (2004). R(+)-methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. Biochem. Biophys. Res. Commun., 324, 621626.
  • HOWLETT, A.C., BARTH, F., BONNER, T.I., CABRAL, G., CASELLAS, P., DEWANE, W.A., FELDE, C.C., HERKENHAM, M., MACKIE, K., MARTIN, B.R., MECHOULAM, R. & PERTWEE, R.G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161202.
  • HOWLETT, A.C., QUALY, J.M. & KHACHATRIAN, L.L. (1986). Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol., 29, 307313.
  • HUESTIS, M.A., SAMPSON, A.H., HOLICKY, B.J., HENNINGFIELD, J.E. & CONC, E.J. (1992). Characterization of the absorption phase of marijuana smoking. Clin. Pharmacol. Ther., 52, 3141.
  • JACOBSSON, S.O., WALLIN, T. & FOWLER, C.J. (2001). Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther., 299, 951959.
  • JONES, S. & HOWL, J. (2003). Cannabinoid receptor systems: therapeutic targets for tumour intervention. Exp. Opin. Ther. Targets, 7, 749758.
  • JORDA, M.A., RAYMAN, N., TAS, M., VERBAKEL, S.E., BATTISTA, N., VAN LOM, K., LOWENBERG, B., MACCARRONE, M. & DELWEL, R. (2004). The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood, 104, 526534.
  • JORDA, M.A., RAYMAN, N., VALK, P., DE WEE, E. & DELWEL, R. (2003). Identification characterization and function of a novel oncogene: the peripheral cannabinoid receptor Cb2. Ann. NY Acad. Sci., 996, 1016.
  • JORDA, M.A., VERBAKEL, S.E., VALK, P.J.M., VANKAN-BERKHOUDT, Y.V., MACCARRONE, M., FINAZZI-AGRO’, A., LOWENBERG, B. & DELWEL, R. (2002). Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to endocannabinoid 2-arachidonoylglycerol. Blood, 99, 27862793.
  • JOSEPH, J., NIGGEMANN, B., ZAENKER, K.S. & ENTSCHLADEN, F. (2004). Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol. Immunother., 53, 723728.
  • JOY, J.E., WATSON Jr, S.J. & BENSON Jr, J.A. eds. (1999). Marijuana and Medicine-assessing the Science Base. Washington, D.C.: Institute of Medicine-National Academy Press.
  • KAWAMORI, T., RAO, C.V., SEIBERT, K. & REDDY, B.S. (1998). Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58, 409412.
  • KEARN, C.S. & HILLARD, C.J. (1997). Rat microglial cells express the peripheral-type cannabinoid receptor (CB2) which is negatively coupled to adenylyl cyclase, Symposium on Cannabinoids, Vol. 1, p. 61, International Cannabinoid Research Society: Burlington, VT.
  • KIM, H.G., KASSIS, J., SOUTO, J.C., TURNER, T. & WELLS, A. (1999). EGF receptor signaling in prostate morphogenesis and tumorigenesis. Histol. Histopathol., 14, 11751182.
  • KISHIMOTO, S., GOKOH, M., OKA, S., MURAMATSU, M., KAJIWARA, T., WAKU, K. & SUGIURA, T. (2003). 2-Arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J. Biol. Chem., 278, 2446924475.
  • KISHIMOTO, S., KOBAYASHI, Y., OKA, S., GOKOH, M., WAKU, K. & SUGIURA, T. (2004). 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J. Biochem. (Tokyo), 135, 517524.
  • KISHIMOTO, S., MURAMATSU, M., GOKOH, M., OKA, S., WAKU, K. & SUGIURA, T. (2005). Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J. Biochem. (Tokyo), 137, 217223.
  • KLEIN, T.W. (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol., 5, 400411.
  • KLEIN, T.W., LANE, B., NEWTON, C.A. & FRIEDMAN, H. (2000). The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med., 225, 18 Review.
  • KLEIN, T.W., NEWTON, C. & FRIEDMAN, H. (1998). Cannabinoid receptors and immunity. Immunol. today, 19, 373.
  • KOKI, A.T., KHAN, N.K., WOERNER, B.M., SEIBERT, K., HARMON, J.L., DANNENBERG, A.J., SOSLOW, R.A. & MASFERRER, J.L. (2002). Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancer. Prostaglandins Leukot. Essent. Fatty Acids, 66, 1318.
  • KUNE, G.A., KUNE, S. & WATSON, L.F. (1988). Colorectal cancer risk, chronic illnesses, operations and medications: a case control results from the Melbourne colorectal cancer study. Cancer Res., 48, 43994404.
  • KUNOS, G., JARAI, Z., BATKAI, S., GOPARAJU, S.K., ISHAC, E.J., LIU, J., WANG, L. & WAGNER, J.A. (2000). Endocannabinoids as cardiovascular modulators. Chem. Phys. Lipids, 108, 159168 Review.
  • KUNOS, G. & PACHER, P. (2004). Cannabinoids cool the intestine. Nat. Med., 10, 678679.
  • KUROI, K. & TOI, M. (2001). Circulating angiogenesis regulators in cancer patients. Int. J. Biol. Markers, 16, 526.
  • LAUFFENBURGER, D.A. & HORWITZ, A.F. (1996). Cell migration: a physically integrated molecular process. Cell, 84, 359369 Review.
  • LIGRESTI, A., BISOGNO, T., MATIAS, I., DE PETROCELLIS, L., CASCIO, M.G., COSENZA, V., D'ARGENIO, G., SCAGLIONE, G., BIFULCO, M., SORRENTINI, I. & DI MARZO, V. (2003). Possible endocannabinoid control of colorectal cancer growth. Gastroenterology, 125, 677687.
  • LIU, J., GAO, B., MIRSHAHI, F., SANYAL, A.J., KHANOLKAR, A.D., MAKRIYANNIS, A. & KUNOS, G. (2000). Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J., 346, 835840.
  • LIU, X.H. & ROSE, D.P. (1996). Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res., 56, 51255127.
  • LIU, X.H., WILEY, H.S. & MEIKLEAW (1993). Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. J. Clin. Endocrinol. Metabol., 77, 14721478.
  • LYNN, A.B. & HERKENHAM, M. (1994). Localization of cannabin receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther., 268, 16121623.
  • MACCARRONE, M. & FINAZZI-AGRÒ, A. (2002). Endocannabinoids and their actions. Vitam. Horm, 65, 225255.
  • MACCARRONE, M., LORENZON, T., BARI, M., MELINO, G. & FINAZZI-AGRÒ, A. (2000). Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem., 275, 3193831945.
  • MACDONALD, J.C. & VAUGHAN, C.W. (2001). Cannabinoids act backwards. Nature, 410, 527530.
  • MACKIE, K. & HILLE, B. (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. U.S.A., 89, 38253829.
  • MACPHEE, D. (1999). Effects of marijuana on cell nuclei: a review of the literature relating to the genotoxicity of cannabis. In: The Health Effects of Cannabis, ed. Kalant H, Corrigall W, Hall WD & Smart R. pp. 435458. Toronto: Centre for Addiction and Mental Health.
  • MARKER, P.C., DONJACOUR, A.A., DAHIYA, R. & CUNHA, G.R. (2003). Hormonal, cellular, and molecular control of prostatic development. Dev. Biol., 253, 165174 Review.
  • MARNETT, L.J. (2002). Recent developments in cyclooxygenase inhibition. Prostaglandins Other Lipid Mediat., 68, 153164.
  • MARSELOS, M. & KARAMANAKOS, P. (1999). Mutagenicity, developmental toxicity and carcinogeneity of cannabis. Addict Biol., 4, 512.
  • MASSI, P., VACCANI, A., CERUTI, S., COLOMBO, A., ABBRACCHIO, M.P. & PAROLARO, D. (2004). Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J. Pharmacol. Exp. Ther., 308, 838845.
  • MATSUDA, L.A., LOLAIT, S.J., BROWNSTEIN, M.J., YOUNG, A.C. & BONNER, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561564.
  • MCALLISTER, S.D., CHAN, C., TAFT, R.J., LUU, T., ABOOD, M.E., MOORE, D.H., ALDAPE, K. & YOUNT, G. (2005). Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J. Neurooncol., 74, 3140.
  • MCALLISTER, S.D. & GLASS, M. (2002). CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot Essent Fatty Acids, 66, 161171.
  • MCCOY, K.L., MATVEYEVA, M., CARLISLE, S.J. & CABRAL, G.A. (1999). Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J. Pharmacol. Exp. Ther., 289, 1620.
  • MCKALLIP, R.J., NAGARKATTI, M. & NAGARKATTI, P.S. (2005). Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol., 174, 32813289.
  • MECHOULAM, R., BEN-SHABAT, S., HANUS, L., LIGUMSKY, M., KAMINSKI, N.E., SCHATZ, A.R., GOPHER, A., ALMOG, S., MARTIN, B.R., COMPTON, D.R., PERTWEE, R.G., GRIFFIN, G., BAYEWITCH, M., BARG, J. & VOGEL, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 50, 8390.
  • MECHOULAM, R., PANIKASHVILI, D. & SHOHAMI, E. (2002). Cannabinoids and brain injury: therapeutic implications. Trends Mol. Med., 8, 5861.
  • MELCK, D., BISOGNO, T., DE PETROCELLIS, L., CHUANG, H., JULIUS, D., BIFULCO, M. & DI MARZO, V. (1999a). Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem. Biophys. Res. Commun., 262, 275284.
  • MELCK, D., DE PETROCELLIS, L., ORLANDO, P., BISOGNO, T., LAEZZA, C., BIFULCO, M. & DI MARZO, V. (2000). Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology, 141, 118126.
  • MELCK, D., RUEDA, D., GALVE-ROPERH, I., DE PETROCELLIS, L., GUZMAN, M. & DI MARZO, V. (1999b). Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett., 463, 235240.
  • MENDIZABAL, V.E. & ADLER-GRASCHINSKY, E. (2003). Cannabinoid system as a potential target for drug development in the treatment of cardiovascular disease. Curr. Vasc. Pharmacol., 1, 301313 Review.
  • MIMEAULT, M., POMMERY, N., WATTEZ, N., BAILLY, C. & HENICHART, JP. (2003). Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate, 56, 112.
  • MOLINA-HOLGADO, E., VELA, J.M., AREVALO-MARTIN, A., ALMAZAN, G., MOLINA-HOLGADO, F., BORRELL, J. & GUAZA, C. (2002). Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci., 22, 97429753.
  • MONTGOMERY, B.T., YOUNG, C.Y., BILHARTZ, D.T., ANDREWS, P.E., PRESCOTT, J.L., THOMPSON, N.F. & TINDALL, D.J. (1992). Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate, 21, 6373.
  • MOORE, R.J., ZWEIFEL, B.S., HEUVELMAN, D.M., LEABY, K.M., EDWARDS, D.A. & WOENER, B.M. (2000). Enhanced antitumor activity by co-administration of celecoxib and the chemotherapeutic agents cyclophosphamide and 5-FU. Proc. Am. Assoc. Cancer Res., 41, 409.
  • MORITA, I. (2002). Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat, 68, 165175.
  • MUNRO, S., THOMAS, K.L. & ABU-SHAAR, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 6165.
  • NA, H.K. & SURH, Y.J. (2002). Induction of cyclooxygenase-2 in Ras-transformed human mammary epithelial cells undergoing apoptosis. Ann. NY Acad. Sci., 973, 153160.
  • NEPTUNE, E.R. & BOURNE, H.R. (1997). Receptors induce chemotaxis by releasing the betagamma subunit of Gi, not by activating Gq or Gs. Proc. Natl. Acad. Sci. U.S.A., 94, 1448914494.
  • NITHIPATIKOM, K., ENDSLEY, M.P., ISBELL, M.A., FALCK, J.R., IWAMOTO, Y., HILLARD, C.J. & CAMPBELL, W.B. (2004). 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res., 64, 88268830.
  • NITHIPATIKOM, K., ENDSLEY, M.P., ISBELL, M.A., WHEELOCK, C.E., HAMMOCK, B.D. & CAMPBELL, W.B. (2005). A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem. Biophys. Res. Commun., 332, 10281033.
  • NUNEZ, E., BENITO, C., PAZOS, M.R., BARBACHANO, A., FAJARDO, O., GONZALEZ, S., TOLON, R.M. & ROMERO, J. (2004). Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse, 53, 208213.
  • OSHIMA, M., MURAI, N., KARGMAN, S., ARGUELLO, M., LUK, P., KWONG, E., TAKETO, M.M. & EVANS, J.F. (2001). Chemoprevention of intestinal polyposis in the APC(delta)716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res., 61, 17331740.
  • PATSOS, H.A., HICKS, D.J., DOBSON, R.R., GREENHOUGH, A., WOODMAN, N., LANE, J.D., WILLIAMS, A.C. & PARASKEVA, C. (2005). The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase-2. Gut, 54, 17411750.
  • PENG, D., FAN, Z., LU, Y., DEBLASIO, T., SCHER, H. & MENDELSOHN, J. (1996). Antiepidermal growth factor receptor monoclonal antibody 225 upregulates p27KiP1 and induces G1 arrest in prostatic carcinoma cell line DU-145. Cancer Res., 56, 36663669.
  • PERTWEE, R.G. (2000). Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert. Opin. Investig. Drugs, 9, 15531571.
  • PETERSEN, G., MOESGAARD, B., SCHMID, P.C., SCHMID, H.H., BROHOLM, H., KOSTELJANETZ, M. & HANSEN, H.S. (2005). Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J. Neurochem., 93, 299309.
  • PIOMELLI, D., GIUFFRIDA, A., CALIGNANO, A. & RODRIGUEZ DE FONSECA, F. (2000). The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci., 21, 218224.
  • PORTELLA, G., LAEZZA, C., LACCETTI, P., DE PETROCELLIS, L., DI MARZO, V. & BIFULCO, M. (2003). Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J., 17, 17711773.
  • PORTER, A.C. & FELDER, C.C. (2001). The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol. Ther., 90, 4560.
  • PRATICO, D., TANGIRALA, R.K., RADER, D.J., ROKACH, J. & FITZGERALD, G.A. (1998). Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat. Med., 4, 11891192.
  • PRESCOTT, S.M. & FITZPATRICK, F.A. (2000). Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta, 1470, 6978 Review.
  • RAK, J., MITSUHASHI, Y., BAYKO, L., FILMUS, J., SHIRASAWA, S., SASAZUKI, T. & KERBEL, R.S. (1995). Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 55, 45754580.
  • RAMER, R., WEINZIERL, U., SCHWIND, B., BRUNE, K. & HINZ, B. (2003). Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. Mol. Pharmacol., 64, 11891198.
  • RAYMAN, N., LAM, K.H., LAMAN, J.D., SIMONS, P.J., LOWENBERG, B., SONNEVELD, P. & DELWEL, R. (2004). Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status. The J. Immunol., 172, 21112117.
  • REILLY, T.P., BRADY, J.N., MARCHICK, M.R., BOURDI, M., GEORGE, J.W., RADONOVICH, M.F., PISE-MASISON, C.A. & POHL, L.R. (2001). A protective role for cyclooxigenase-2 in drug induced liver injury in mice. Chem. Res. Toxixol., 14, 16201628.
  • RIGAS, B., GOLDMAN, I.S. & LEVINE, L. (1993). Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 122, 518523.
  • ROLLAND, P.H., MARTIN, P.M., JACQUEMIER, J., ROLLAND, A.M. & TOGA, M. (1980). Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Inst., 64, 10611070.
  • ROMANO, M. & CLÀRIA, J. (2003). Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J., 17, 19861995.
  • ROTH, M.D., MARQUES-MAGALLANES, J.A., YUAN, M., SUN, W., TASHKIN, D.P. & HANKINSON, O. (2001). Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am. J. Resp. Cell Mol. Biol., 24, 339344.
  • RUEGG, C., ZARIC, J. & STUPP, R. (2003). Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality. Ann. Med., 35, 476487 Review.
  • RUIZ, L., MIGUEL, A. & DIAZ-LAVIADA, I. (1999). Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett., 458, 400404.
  • SALZET, M., BRETON, C., BISOGNO, T. & DI MARZO, V. (2000). Comparative biology of the endocannabinoid system possible role in the immune response. Eur. J. Biochem., 267, 49174927 Review.
  • SANCHEZ, C., DE CEBALLOS, M.L., DEL PULGAR, T.G., RUEDA, D., CORBACHO, C., VELASCO, G., GALVE-ROPERH, I., HUFFMAN, J.W., RAMON Y CAJAL, S. & GUZMAN, M. (2001a). Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res., 61, 57845789.
  • SANCHEZ, C., GALVE-ROPERH, I., CANOVA, C., BRACHET, P. & GUZMAN, M. (1998). Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett., 436, 610.
  • SANCHEZ, C., RUEDA, D., SEGUI, B., GALVE-ROPERH, I., LEVADE, T. & GUZMAN, M. (2001b). The CB(1) cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan. Mol. Pharmacol., 59, 955959.
  • SANCHEZ, M.G., SANCHEZ, A.M., RUIZ-LLORENTE, L. & DIAZ-LAVIADA, I. (2003). Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Lett., 555, 561566.
  • SARFARAZ, S., AFAQ, F., ADHAMI, V.M. & MUKHTAR, H. (2005). Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res., 65, 16351641.
  • SARAFIAN, T.A., MAGALLANES, J.A., SHAU, H., TASHKIN, D. & ROTH, M.D. (1999). Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. Am. J. Respir Cell Mol. Biol., 20, 12861293.
  • SARAFIAN, T.A., TASHKIN, D.P. & ROTH, M.D. (2001). Marijuana smoke and delta(9)-tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated apoptosis. Toxicol. Appl. Pharmacol., 174, 264272.
  • SCHLICKER, E. & KATHMANN, M. (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci., 22, 565572 Review.
  • SHIBATA, R., SATO, K., PIMENTEL, D.R., TAKEMURA, Y., KIHARA, S., OHASHI, K., FUNAHASHI, T., OUCHI, N. & WALSH, K. (2005). Adiponectin protects against myocardial ischemia–reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med., 11, 10961103.
  • SIMON, W.E., PAHNKE, V.G. & HOLZEL, F. (1985). In vitro modulation of prolactin binding to human mammary carcinoma cells by steroid hormones and prolactin. J. Clin. Endocrinol. Metab., 60, 12431249.
  • SMART, D., GUNTHORPE, M.J., JERMAN, J.C., NASIR, S., GRAY, J., MUIR, A.I., CHAMBERS, J.K., RANDALL, A.D. & DAVIS, J.B. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol., 129, 227230.
  • SONG, Z.H. & ZHONG, M. (2000). CB1 cannabinoid receptor-mediated cell migration. J. Pharmacol. Exp. Ther., 294, 204209.
  • SRIVASTAVA, M.D., SRIVASTAVA, B.I. & BROUHARD, B. (1998). Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology, 40, 179185.
  • STAMEY, T.A., YANG, N., HAY, A.R., MCNEAL, J.E., FREIHA, F.S. & REDWINE, E. (1987). Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med., 317, 909916.
  • STEINBACH, G., LYNCH, P.M., PHILLIPS, R.K., WALLACE, M.H., HAWK, E., GORDAN, G.B., WAKABAYASHI, N., SAUNDERS, B., SHEN, Y., FUJIMURA, T., SU, L., LEVIN, B., DUBOIS, HITTELMAN, W.H., ZIMMERMAN, S., SHERMAN, J.W. & KELLOFF, G. (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor in familial adenomatous polyposis. N. Engl. J. Med., 342, 19461952.
  • STINCHCOMB, A., CHALLAPALLI, P., HARRIS, K. & BROWE, J. (2001). Optimization of in vitro experimental conditions for measuring the percutaneous absorption of Δ9-THC, cannabidiol, and WIN55,212-2, Symposium on the Cannabinoids, p. 161. Burlington, Vermont: International Cannabinoid Research Society.
  • STRAIKER, A., STELLA, N., PIOMELLI, D., MACKIE, K., KARTEN, H.J. & MAGUIRE, G. (1999). Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system. Proc. Natl. Acad. Sci. U.S.A., 96, 1456514570.
  • SUGIURA, T., KONDO, S., SUKAGAWA, A., NAKANE, S., SHINODA, A., ITOH, K., YAMASHITA, A. & WAKU, K. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 215, 8997.
  • SUGIURA, T., OKA, S., GOKOH, M., KISHIMOTO, S. & WAKU, K. (2004). New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. J. Pharmacol. Sci., 96, 367375 Review.
  • TOMIDA, I., PERTWEE, R.G. & AZUARA-BLANCO, A. (2004). Cannabinoids and glaucoma. Br. J. Ophthalmol., 88, 708713.
  • TRIFAN, O.C., DURHAM, W.F., SALAZAR, V.S., HORTON, J., LEVINE, B.D., ZWEIFEL, B.S., DAVIS, T.W. & MASFERRER, J.L. (2002). Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res., 62, 57785784.
  • TSUJII, M. & DUBOIS, R.N. (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83, 493501.
  • TSUJII, M., KAWANO, S. & DUBOIS, R.N. (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U.S.A., 94, 33333336.
  • TSUJII, M., KAWANO, S., TSUJI, S., SAWAOKA, H., HORI, M. & DUBOIS, R.N. (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93, 705716.
  • VACCANI, A., MASSI, P., COLOMBO, A., RUBINO, T. & PAROLARO, D. (2005). Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br. J. Pharmacol., 144, 10321036.
  • VALK, PJ., HOL, S., VANKAN, Y., IHLE, J.N., ASKEW, D., JENKINS, N.A., GILBERT, D.J., COPELAND, N.G., DE BOTH, N.J., LOWENBERG, B. & DELWEL, R. (1997). The genes encoding the peripheral cannabinoid receptor and alpha-L-fucosidase are located near a newly identified common virus integration site, Evi11. J. Virol., 71, 67966804.
  • WALTER, L., FRANKLIN, A., WITTING, A., WADE, C., XIE, Y., KUNOS, G., MACKIE, K. & STELLA, N. (2003). Non-psychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci., 23, 13981405.
  • WARE, J.L. (1993). Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metast. Rev., 12, 287301.
  • WU, X., RUBIN, M., FAN, Z., DEBLASIO, T., SOOS, T., KOFF, A. & MENDELSOHN, J. (1996). Involvement of p27KiP1 in G1 arrest mediated by an antiepidermal growth factor receptor monoclonal antibody. Oncogene, 12, 13971403.
  • YE, D., MENDELSOHN, J. & FAN, Z. (1999). Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27KiP1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin. Cancer Res., 5, 21712177.
  • ZHA, S., YEGNASUBRAMANIAN, V., NELSON, W.G., ISAACS, W.B. & DE MARZO, A.M. (2004). Cyclooxygenases in cancer: progress and perspective. Cancer Lett., 215, 120 Review.
  • ZHU, L.X., SHARMA, S., STOLINA, M., GARDNER, B., ROTH, M.D., TASHKIN, D.P. & DUBINETT, S.M. (2000). Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J. Immunol., 165, 373380.
  • ZYGMUNT, P.M., JULIUS, I., DI MARZO, I. & HOGESTATT, E.D. (2000). Anandamide – the other side of the coin. Trends Pharmacol. Sci., 21, 4344.